PNT News and Press, POINT Biopharma Global Inc. From 11/14/23

2023-11-14 02:11:42 ET Summary POINT Biopharma Global is currently trading above Eli Lilly's tender offer price of $12.50. The reason for this is that the market believes that a second bidder may emerge, and the tea leaves support this possibility. BVF fund has refused to tend...

2023-11-13 07:51:48 ET More on POINT Biopharma Global Eli Lilly POINTs Toward Radiopharmaceutical Ambitions Eli Lilly extends expiration of tender offer to acquire Point Biopharma Point Biopharma quickly gains as big holder comes out against Eli Lilly deal Se...

INDIANAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the t...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

POINT Biopharma Global Inc. (PNT) is expected to report $-0.3 for Q3 2023

2023-11-10 15:00:22 ET More on the markets Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble SPY: Double-Barreled Buy Signal Works Again, Now What? SPY: Don't Believe Mr. Market And Stay On The Sidelines Invest...

2023-11-09 13:43:19 ET Summary Eli Lilly received FDA approval to sell tirzepatide for obesity treatment, expanding its market beyond diabetes. Shares of Eli Lilly jumped 3.2% on the news, resulting in a $17.3 billion increase in shareholder wealth. Tirzepatide has shown promi...

2023-11-09 06:42:09 ET Summary Actors and studios have reached a tentative deal to end a strike that lasted almost four months. AMC Entertainment reports a surge in revenue in Q3, boosted by the success of summer releases Barbie and Oppenheimer. Eli Lilly extends expiration of...

2023-11-08 19:27:26 ET More on Eli Lilly, Point Biopharma Global Eli Lilly and Co (LLY) Q3 2023 Earnings Conference Call Transcript Eli Lilly and Company 2023 Q3 - Results - Earnings Call Presentation Eli Lilly wins FDA approval for weight loss therapy (update) ...

Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma PR Newswire INDIANAPOLIS , Nov. 8, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued an...